CTLA4 and pancreatic neoplasm: Despite the emergence of immune checkpoint blockade as a promising new treatment for cancers, a majority of cancer patients, including pancreatic cancer patients, do not benefit from monotherapy with PD-L1 or CTLA-4 blockade [1, 2].